Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Interest & Investment Income (2016 - 2026)

Intellia Therapeutics has reported Interest & Investment Income over the past 11 years, most recently at $5.2 million for Q1 2026.

  • Quarterly Interest & Investment Income fell 39.5% to $5.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $25.8 million through Mar 2026, down 41.07% year-over-year, with the annual reading at $29.2 million for FY2025, 38.93% down from the prior year.
  • Interest & Investment Income was $5.2 million for Q1 2026 at Intellia Therapeutics, down from $6.5 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $12.7 million in Q3 2023 and troughed at $540000.0 in Q1 2022.
  • The 5-year median for Interest & Investment Income is $8.6 million (2025), against an average of $8.3 million.
  • Year-over-year, Interest & Investment Income skyrocketed 2118.52% in 2023 and then tumbled 44.61% in 2025.
  • A 5-year view of Interest & Investment Income shows it stood at $5.4 million in 2022, then surged by 132.7% to $12.5 million in 2023, then decreased by 14.67% to $10.6 million in 2024, then plummeted by 39.08% to $6.5 million in 2025, then dropped by 19.63% to $5.2 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Interest & Investment Income are $5.2 million (Q1 2026), $6.5 million (Q4 2025), and $6.7 million (Q3 2025).